Therapeutic Potential of Mitragyna speciosa in Neuropathic Pain and Neurodegenerative Disorders: A Literature Review

Alfan Adika Rahman; Yogi Ertanto

doi:10.69693/ijmst.v4i3.12853

Authors

Alfan Adika Rahman Indonesia Defense University
Yogi Ertanto Indonesia Defense University

DOI:

https://doi.org/10.69693/ijmst.v4i3.12853

Keywords:

Mitragyna Speciosa, Kratom, Mitragynine, Neuropathic Pain, Drug Interactions

Abstract

Kratom (Mitragyna speciosa) contains active alkaloids, primarily mitragynine and 7-hydroxymitragynine, which interact with the opioid, adrenergic, serotonergic, and cannabinoid systems. This review assesses primary evidence from 2020–2025 regarding neuropathic pain, cognitive or neurodegenerative effects, and pharmacokinetics and drug interactions. Three structured searches were conducted in PubMed/MEDLINE on June 16, 2026, yielding 90 records. After removing seven duplicates, 83 unique records were screened. A total of 29 reports were further assessed, and 17 primary studies met criteria. Citation and title searches added four reports, three of which met criteria, for a total of 20 studies. The evidence for pain comes primarily from animal models of chemotherapy-induced neuropathy and suggests that mitragynine may reduce allodynia through adrenergic, opioid, and cannabinoid mechanisms. Human evidence for analgesic effectiveness is observational and does not prove causality. In the cognitive domain, preclinical findings more frequently indicate impairments in learning, memory, and hippocampal plasticity with high-dose or prolonged exposure. Its therapeutic potential against Alzheimer's disease is supported by docking, in vitro AChE inhibition, and network pharmacology. Human pharmacokinetic studies indicate prolonged mitragynine exposure and potential interactions via CYP3A, while preliminary single-dose clinical data demonstrate short-term tolerability but do not yet address the safety of chronic use. Overall, kratom has consistent preclinical analgesic signals, but clinical evidence for therapeutic use in neuropathic pain and neurodegenerative disorders remains inadequate.

References

Buckhalter, S., Wallace, C. W., Wideheim, M., Unche-Okoroha, C., Mesangeau, C., Mccurdy, C. R., & Mcmahon, L. R. (2021). The Antidepressant-Like And Analgesic Effects Of Kratom Alkaloids Are Accompanied By Changes In Low Frequency Oscillations But Not Δfosb Accumulation. Frontiers In Pharmacology, 12, 696461. Https://Doi.Org/10.3389/Fphar.2021.696461

Farkas, D. J., Foss, J. D., & Cichewicz, R. H. (2022). Kratom Alkaloid Mitragynine: Inhibition Of Chemotherapy-Induced Peripheral Neuropathy In Mice Is Dependent On Sex And Active Adrenergic And Opioid Receptors. IBRO Neuroscience Reports, 13, 198–206. Https://Doi.Org/10.1016/J.Ibneur.2022.08.007

Farkas, D. J., Salyer, F., & Cichewicz, R. H. (2023). Cannabinoid Mechanisms Contribute To The Therapeutic Efficacy Of The Kratom Alkaloid Mitragynine Against Neuropathic, But Not Inflammatory Pain. Life Sciences, 328, 121878. Https://Doi.Org/10.1016/J.Lfs.2023.121878

Foss, J. D., Nayak, S. U., & Cichewicz, R. H. (2020). Mitragynine, Bioactive Alkaloid Of Kratom, Reduces Chemotherapy-Induced Neuropathic Pain In Rats Through Α-Adrenoceptor Mechanism. Drug And Alcohol Dependence, 209, 107946. Https://Doi.Org/10.1016/J.Drugalcdep.2020.107946

Hooijmans, C. R., Rovers, M. M., De Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Inthout, J. (2014). SYRCLE’s Risk Of Bias Tool For Animal Studies. BMC Medical Research Methodology, 14, 43. Https://Doi.Org/10.1186/1471-2288-14-43

Hossain, M. A., Rahman, M. M., & Islam, M. T. (2024). Network Pharmacology, Molecular Docking, And In Vitro Insights Into The Potential Of Mitragyna Speciosa For Alzheimer’s Disease. International Journal Of Molecular Sciences, 25(23), 13201. Https://Doi.Org/10.3390/Ijms252313201

Huestis, M. A., Brett, M. A., Bothmer, J., & Atallah, R. (2024). Human Mitragynine And 7-Hydroxymitragynine Pharmacokinetics After Single And Multiple Daily Doses Of Oral Encapsulated Dried Kratom Leaf Powder. Molecules, 29(5), 984. Https://Doi.Org/10.3390/Molecules29050984

Iman, I. N., Ahmad, N. A., & Hassan, Z. (2021). Mitragynine (Kratom)-Induced Cognitive Impairments In Mice Resemble Δ^9-THC And Morphine Effects: Reversal By Cannabinoid CB_1 Receptor Antagonism. Frontiers In Pharmacology, 12, 708055. Https://Doi.Org/10.3389/Fphar.2021.708055

Indriani, D. W., Wibowo, A., & Suharjono, S. (2025). Serotonin Release Mediates Analgesia Via Opioidergic System And Withdrawal Symptoms In Chronic Kratom Extract-Treated Mice. BMC Complementary Medicine And Therapies, 25, 205. Https://Doi.Org/10.1186/S12906-025-04947-2

Innok, W., Hiranrat, A., Chana, N., Rungrotmongkol, T., & Kongsune, P. (2021). In Silico And In Vitro Anti-Ache Activity Investigations Of Constituents From Mytragyna Speciosa For Alzheimer’s Disease Treatment. Journal Of Computer-Aided Molecular Design, 35(3), 325–336. Https://Doi.Org/10.1007/S10822-020-00372-4

Kamble, S. H., Sharma, A., King, T. I., León, F., Mccurdy, C. R., & Avery, B. A. (2020). Exploration Of Cytochrome P450 Inhibition Mediated Drug-Drug Interaction Potential Of Kratom Alkaloids. Toxicology Letters, 319, 148–154. Https://Doi.Org/10.1016/J.Toxlet.2019.11.005

Mongar, P., Jaisi, A., Inkviya, T., Wungsintaweekul, J., & Wiwattanawongsa, K. (2024). Effects Of Itraconazole On Pharmacokinetics Of Mitragynine And 7-Hydroxymitragynine In Healthy Volunteers. ACS Pharmacology & Translational Science, 7(3), 823–833. Https://Doi.Org/10.1021/Acsptsci.3c00335

Mun, C. J., Strickland, J. C., & Garcia-Romeu, A. (2025). Kratom (Mitragyna Speciosa) Use For Self-Management Of Pain: Insights From Cross-Sectional And Ecological Momentary Assessment Data. The Journal Of Pain, 26, 104726. Https://Doi.Org/10.1016/J.Jpain.2024.104726

Ortiz, Y. T., Mccurdy, C. R., & Mcmahon, L. R. (2023). Cannabidiol And Mitragynine Exhibit Differential Interactive Effects In The Attenuation Of Paclitaxel-Induced Mechanical Allodynia, Acute Antinociception, And Schedule-Controlled Responding In Mice. Pharmacological Reports, 75(4), 937–950. Https://Doi.Org/10.1007/S43440-023-00498-W

Page, M. J., Mckenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., & Moher, D. (2021). The PRISMA 2020 Statement: An Updated Guideline For Reporting Systematic Reviews. BMJ, 372, N71. Https://Doi.Org/10.1136/Bmj.N71

Prevete, E., Kuypers, K. P. C., Theunissen, E. L., & Ramaekers, J. G. (2025). An Exploratory Study Of The Safety Profile And Neurocognitive Function After Single Doses Of Mitragynine In Humans. Psychopharmacology, 242(6), 1363–1376. Https://Doi.Org/10.1007/S00213-024-06734-2

Rethlefsen, M. L., Kirtley, S., Waffenschmidt, S., Ayala, A. P., Moher, D., Page, M. J., & Koffel, J. B. (2021). PRISMA-S: An Extension To The PRISMA Statement For Reporting Literature Searches In Systematic Reviews. Systematic Reviews, 10, 39. Https://Doi.Org/10.1186/S13643-020-01542-Z

Suhaimi, F. W., Hassan, Z., & Müller, C. P. (2023). Kratom (M. Speciosa) Exposure During Adolescence Caused Long-Lasting Cognitive Behavioural Deficits Associated With Perturbated Brain Metabolism Pathways In Adult Rats. Behavioural Brain Research, 446, 114411. Https://Doi.Org/10.1016/J.Bbr.2023.114411

Tanna, R. S., Candiotti, K. A., & Mccune, J. S. (2022). Clinical Pharmacokinetic Assessment Of Kratom (Mitragyna Speciosa), A Botanical Product With Opioid-Like Effects, In Healthy Adult Participants. Pharmaceutics, 14(3), 620. Https://Doi.Org/10.3390/Pharmaceutics14030620

Tanna, R. S., Nguyen, J. T., & Mccune, J. S. (2023). Clinical Assessment Of The Drug Interaction Potential Of The Psychotropic Natural Product Kratom. Clinical Pharmacology & Therapeutics, 113(6), 1315–1325. Https://Doi.Org/10.1002/Cpt.2891

Yunusa, S., Hassan, Z., & Müller, C. P. (2023). Mitragynine Inhibits Hippocampus Neuroplasticity And Its Molecular Mechanism. Pharmacological Reports, 75(6), 1488–1501. Https://Doi.Org/10.1007/S43440-023-00541-W

Yunusa, S., Müller, C. P., & Hassan, Z. (2024). Mitragynine (Kratom)—Withdrawal Behaviour And Cognitive Impairments Can Be Ameliorated By An Epigenetic Mechanism. British Journal Of Pharmacology, 181(13), 2070–2084. Https://Doi.Org/10.1111/Bph.16352

Zul Aznal, A. N., Suhaimi, F. W., & Hassan, Z. (2022). Adolescent Kratom Exposure Affects Cognitive Behaviours And Brain Metabolite Profiles In Sprague-Dawley Rats. Frontiers In Pharmacology, 13, 1057423. Https://Doi.Org/10.3389/Fphar.2022.1057423